HSCT is effective in patients with PSTPIP1-associated myeloid-related proteinemia inflammatory (PAMI) syndrome.

Capsule summary: In some patients with PAMI syndrome, no complete response to anti-cytokine and immunosuppressive therapy of on-going autoinflammation and cytopenias could be achieved. Allogeneic HSCT in these patients provided cure for disease symptoms.

Source: Journal of Allergy and Clinical Immunology - December 14, 2020 Category: Allergy & Immunology Authors: Alexandra Laberko, Vasiliy Burlakov, Sarah Maier, Mario Abinun, Roderick Skinner, Anna Kozlova, Deepti Suri, Kai Lehmberg, Ingo M üller, Dmitry Balashov, Galina Novichkova, Dirk Holzinger, Andrew R. Gennery, Anna Shcherbina Source Type: research